Boston Scientific

Boston Scientific Corporation stands as one of the world's preeminent medical device manufacturers, dedicated to transforming lives through innovative medical solutions that improve patient health globally. Founded in 1979 by Pete Nicholas and John Abele, the company pioneered the development of less-invasive medical procedures through its revolutionary steerable catheters, fundamentally changing how physicians treat disease. Today, Boston Scientific operates as a multinational biotechnology and biomedical engineering firm serving interventional medical specialties across cardiology, electrophysiology, endoscopy, neuromodulation, peripheral interventions, and numerous surgical specialties.

The company's expansive portfolio encompasses thousands of medical devices deployed across hospitals and healthcare facilities worldwide. With approximately 63,000 employees and operations spanning the globe, Boston Scientific has established itself as a market leader in multiple medical device categories. The company's two primary business segments—Cardiovascular (64% of revenue) and MedSurg (36% of revenue)—deliver comprehensive solutions for treating some of medicine's most challenging conditions, from cardiac arrhythmias and coronary artery disease to gastrointestinal disorders and chronic pain management.

In fiscal year 2024, Boston Scientific achieved exceptional financial performance with revenue of $16.75 billion, representing 17.6% growth year-over-year, and net income of $1.85 billion. The company's success stems from its relentless commitment to meaningful innovation, evidenced by groundbreaking products like the WATCHMAN FLX left atrial appendage closure device, the AGENT drug-coated balloon (the first FDA-approved coronary DCB in the U.S.), and the modular cardiac rhythm management system combining an implantable defibrillator with a leadless pacemaker. With a market capitalization of approximately $146 billion as of 2025, Boston Scientific continues to strengthen its market position through strategic acquisitions, including the $3.7 billion purchase of Axonics and the $1.28 billion acquisition of Silk Road Medical in 2024.

Under the leadership of Chairman and CEO Mike Mahoney since 2012, Boston Scientific has transformed into a high-growth medical technology powerhouse. The company's culture emphasizes caring, meaningful innovation, high performance, global collaboration, diversity, and a winning spirit—values that have propelled organic revenue growth projections of 12-14% for 2025. With over 99% pay equity across its workforce and 91% of employees expressing pride in working for the company, Boston Scientific has cultivated an environment where purposeful work and innovation converge to create a healthier society. As the medical device industry evolves toward more personalized, less-invasive treatments, Boston Scientific remains at the forefront, investing heavily in next-generation technologies that will define the future of patient care.